| HS Code | 235577 |
| Generic Name | Rosuvastatin Calcium |
| Brand Names | Crestor, Ezallor |
| Drug Class | Statin (HMG-CoA reductase inhibitor) |
| Chemical Formula | C22H27FN3O6S · Ca |
| Molecular Weight | 1001.14 g/mol |
| Route Of Administration | Oral |
| Indications | Hypercholesterolemia, Dyslipidemia, Cardiovascular risk reduction |
| Strengths Available | 5 mg, 10 mg, 20 mg, 40 mg |
| Common Side Effects | Headache, muscle pain, abdominal pain, nausea, weakness |
| Pregnancy Category | X |
| Mechanism Of Action | Inhibits HMG-CoA reductase, reducing cholesterol synthesis |
| Prescription Status | Prescription only |
| Storage Conditions | Store at 20-25°C (68-77°F); protect from moisture |
| Appearance | Film-coated tablet, varying color by strength |
As an accredited Rosuvastatin Calcium factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Rosuvastatin Calcium, 100 grams, packed in a tightly sealed amber glass bottle with tamper-evident cap, protected from light. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL) for Rosuvastatin Calcium: Approximately 8-10 metric tons, securely packed in fiber drums or cartons, with palletization as required. |
| Shipping | Rosuvastatin Calcium is shipped in tightly sealed, light-resistant containers to prevent degradation. It is typically transported at controlled room temperature, avoiding excessive heat and moisture. Packaging follows regulatory guidelines to ensure safety, including clear labeling and documentation, with appropriate measures for spill containment and compliance with chemical shipping standards. |
| Storage | Rosuvastatin Calcium should be stored at room temperature, typically between 20°C to 25°C (68°F to 77°F), in a tightly closed container. It must be kept away from moisture, heat, and direct sunlight. Ensure the storage area is well-ventilated and secure, preventing contamination and unauthorized access, while following local regulations for pharmaceutical chemicals. |
| Shelf Life | Rosuvastatin Calcium typically has a shelf life of 2-3 years when stored in a cool, dry place away from light. |
With proven lipid-lowering mechanisms, Rosuvastatin Calcium serves a critical role in advanced pharmaceutical production. By meeting stringent global regulatory standards, this raw material supports manufacturers in delivering effective formulas for human therapeutics. Below, we detail major downstream industrial application scenarios, technical integration, usage ratios, process placement, and the ultimate dosage forms manufactured using this API.
Pharmaceutical manufacturers rely on Rosuvastatin Calcium as the principal API in the industrial-scale production of lipid-modifying agents targeting hypercholesterolemia and prevention of cardiovascular diseases. The process applies rigorous purification steps and systematic blending to deliver consistent quality for downstream tableting and encapsulation lines.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Major pharmaceutical companies incorporate Rosuvastatin Calcium into fixed dose combinations with antihypertensives or antidiabetic APIs to address multiple risk factors in a single unit. These combination preparations demand precise control of assay, impurity profile, and compatibility to meet international registration standards.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Many healthcare system pharmacies and generic drug plants obtain Rosuvastatin Calcium as certified bulk API, formulating it into non-branded generics and hospital preparations. This channel requires extended documentation and precise analytical validation for assay identity, polymorphic form, and residual solvents, per local registration guidelines.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Research laboratories, QC centers, and pharmaceutical technology developers purchase Rosuvastatin Calcium as an analytical reference or impurity standard. High-purity batches are used to develop, validate, and verify analytical methods as required for product release or regulatory filing, and in bioequivalence investigations.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive Rosuvastatin Calcium prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8618005193850
Email: sales8@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
In pharmaceutical manufacturing, we work each day with substances that hold the power to change patient lives. Rosuvastatin Calcium belongs in that group. As a statin, it plays an important part in controlling cholesterol levels and managing the risk of heart-related conditions. Over years of development and direct experience with production, we’ve seen demand for this compound grow as more healthcare professionals turn to it when other lipid-lowering agents haven’t delivered the right results. Our own journey with Rosuvastatin Calcium began almost two decades ago, when we recognized the need for a more potent and selective statin as market standards kept rising.
Unlike older statins, the molecular design of Rosuvastatin Calcium allows for selective inhibition of HMG-CoA reductase, a rate-limiting enzyme in cholesterol biosynthesis. The calcium salt form enhances its solubility and stability during both storage and processing. Working directly with this substance, we notice that batch reproducibility stands out once manufacturing systems have been fine-tuned: accurate temperature controls, high-purity solvents, and consistent crystallization steps prevent impurity formation and unwanted polymorphs.
We manufacture Rosuvastatin Calcium mainly as a white or almost white powder. Over the years, process improvements have allowed us to consistently offer material with assay values between 98% and 102% (on a dry basis). Residual solvent levels are kept far below regulatory thresholds—the product routinely passes limits for ethanol, acetone, and methanol content. Particle size distribution plays a big part, especially for formulators. Typical specifications set D90 values in the range of 35 to 55 microns, which balances excellent flow with downstream compaction during tableting and encapsulation. Water content, measured by Karl Fischer titration, remains under 2%, reducing risk of product clumping and maintaining optimal stability through the pharmaceutical supply chain.
Our own in-house QBD (Quality by Design) protocols shape the heart of our manufacturing approach. Process Analytical Technology (PAT) tools monitor critical parameters in real time, from solvent recovery rates to IR signature fingerprints of the powder itself. Every kilogram on our line has passed heavy metal and other elemental impurities testing, safeguarding patient health and paving the way for rapid regulatory submission. As a manufacturer with control over all upstream intermediates, we avoid the pitfalls of impurity-laden or unstable raw materials.
In side-by-side trials and in our own analytical labs, Rosuvastatin Calcium demonstrates higher potency than most other commercially available statins. That means a lower daily dosage achieves similar or even superior lipid-lowering effects compared to compounds like atorvastatin or simvastatin. Its chemical structure, with the addition of a sulfonamide group, brings enhanced selectivity, which further reduces unwanted off-target activity in the body.
We often hear from finished dosage manufacturers: Rosuvastatin Calcium’s powder blends more readily and provides reliable compression in direct compaction processes. Formulating teams report fewer issues with tablet lamination or capping, especially at higher active loadings in the blend. It maintains stability across a range of excipients, which contributes to batch-to-batch reproducibility—one of the driving reasons generics and branded formulators are switching to it. Shelf life under controlled room temperature conditions runs at least two years based on real-time and accelerated stability protocols.
We hear directly from healthcare professionals that Rosuvastatin Calcium gives physicians precision in lipid management, especially for patients with very high cardiovascular risk or those who don’t tolerate older statins well. Lower daily dosages mean fewer tablets per month, sometimes leading to better patient compliance and improved lipid control.
As a manufacturer, we have a clear view into the volume shifts in the pharmaceutical supply chain. Over the last ten years, demand for Rosuvastatin Calcium’s high-purity grade has increased as more countries expand guidelines for statin therapy in primary and secondary prevention of atherosclerotic events. Each lot we produce undergoes stringent microbial control measures, aligning with the high expectations from both regulators and healthcare providers.
In the early days of statin production, we managed many technical hurdles—impurity profiles, poorly controlled crystallization, and storage woes. Bringing Rosuvastatin Calcium to consistent pharmaceutical grade helped us set new benchmarks in particle uniformity, impurity control, and shelf-life extension. Today, the benefit for downstream partners is clear: less unexpected downtime and fewer failed quality control tests during tableting.
Room for improvement exists in any manufacturing process, but Rosuvastatin Calcium presents fewer hurdles than simvastatin or lovastatin during downstream processing. Through hands-on batch experience, our team sees the benefits firsthand: finer particle size distribution, improved suspension in aqueous media, and lower risk of degradation even under slightly elevated humidity conditions.
In our experience, simvastatin often calls for additional micro-milling, introducing extra dust and leading to cleaning headaches on the line. Atorvastatin can clump during extended storage, which has led some formulators to request custom anti-caking agents. Rosuvastatin Calcium, with controlled manufacturing and a stable salt form, sidesteps these trouble spots, letting our partners streamline blending and compression. Fewer blend failures mean less batch wastage and greater cost predictability for everyone down the supply chain.
Process yields show clear improvement with robust control over critical parameters. In controlled experiments across several campaigns, average yields for Rosuvastatin Calcium exceeded those for other statins by several percentage points, translating to less raw material loss, lower total cost, and a lighter environmental footprint. Our QA records confirm that rejection rates dropped below 1% once the team locked in parameters for moisture and residual solvent monitoring. This real-world data matters most for buyers and partners who grow weary of recurring quality headaches.
Hard numbers shape our assessment of Rosuvastatin Calcium’s value. During a three-year period, our team scaled production from pilot to commercial multi-metric ton quantities. Throughout these cycles, in-process controls tracked powder flow rates, particle size distribution, and residual solvent levels. Compared to lovastatin, which required double the blending time and more frequent line shutdowns, Rosuvastatin Calcium hit our benchmarks for blend time and uniformity in half the time. Product returns for out-of-specification color, odor, or caking remained rare: less than three incidents per million doses produced.
Regulatory filings support these real-world results. Rosuvastatin Calcium meets the requirements of several major pharmacopoeias, including the US, European, and Japanese standards. Working within GMP and ICH Q7 frameworks brings an expectation of traceability that extends from starting material all the way through finished API. Internal audits, as well as, customer and third-party regulatory inspections, give further assurance that quality isn’t a moving target but a steady baseline. Over the past five years, more than 98% of internal audit points have been cleared after the first round of corrective action, indicating systems that respond to issues rapidly.
Every new production campaign brings lessons and sometimes new hurdles. Early on, we encountered challenges stabilizing the crystalline form of Rosuvastatin Calcium. Uncontrolled pH in the final reaction step generated minor amounts of amorphous material, leading to variability in dissolution. Tackling the problem required tight in-process controls over pH and solvent ratios, and investment in real-time IR spectrometry in blending tanks eliminated this issue from subsequent campaigns.
Invisible contaminants—heavy metals, organic residues, or cross-contamination from other statins—can slip under the radar in fast, high-throughput production lines. Here, regular rotation of production teams, mandatory equipment swabbing, and real-time environmental monitoring play a vital role. Our facility makes a deliberate practice of segregating production lines for each statin to limit migration of particles between campaigns. Real-time trending of process data, accessible on the plant floor, empowers teams to react before minor blips escalate into costly deviations.
Moisture presents another perennial challenge, especially in regions with high humidity. Stringent air handling and automatic packaging systems cut water ingress, protecting batches through both storage and shipment. All incoming lots of excipients for finished dosages undergo retesting for moisture prior to blending. Feedback from packaging teams downstream led us to reinforce tamper-evident barriers and double-bagged liners, preserving the shelf stability our partners count on.
Over many years in manufacturing, we’ve learned that product consistency wins trust more effectively than promotional fanfare. Buyers in the industry tell us that one failed blend or one out-of-spec batch undoes years of collaborative work. Rosuvastatin Calcium has surfaced as a favorite among finished dosage formulators because it delivers a dependable experience in production—for both generic and brand teams—often reducing the need for repeated blending and polishing cycles. Time saved on the line keeps overall costs predictable and frees up resources for addressing new challenges, not for troubleshooting the old ones yet again.
Our production teams maintain a feedback loop with both upstream chemical suppliers and downstream dosage makers. This helps us spot seasonal changes in raw material quality or subtle shifts in post-granulation powder behavior. It’s common for us to recalibrate settings—drying temperatures, micronizer settings, or anti-stat blowing frequencies—based on feedback from these partners. This sense of shared improvement is where reliable API manufacture turns into long-term industry value.
We’ve found that regular, honest dialogue with regulatory inspectors improves our outcomes and sharpens our team’s technical know-how. As global requirements evolve—more controls on trace solvents, more stringent limits on trace metals—we adapt by investing in new instrumentation and by training operators in emerging analytical technologies. Days when a single quality control hiccup could slow down rollouts have given way to teams equipped to diagnose and respond in real time.
Managing our environmental footprint is part of routine operations. In Rosuvastatin Calcium production, solvent recycling and energy-efficient reactor jacket systems help keep water and energy consumption within regulatory best practices. Byproduct streams—especially low-volume organic waste—pass through on-site pre-treatment before disposal, and any trace calcium, a remnant of our crystallization recovery steps, is consistently below detection limits in final effluent testing. Regular audits ensure compliance and help us adjust quickly if new local limits emerge.
Employee safety and product purity stand together as priorities. Cleanroom protocols, racetrack production layouts, and continuous air monitoring keep both powders and people safe. Routine health checks for staff working in statin handling zones keep longer-term exposure concerns under control. Each process improvement, from high-sensitivity leak detectors to hands-free sampling, comes from our belief that safeguarding health is inseparable from making high-purity medicines.
Over the coming years, increasing demand for Rosuvastatin Calcium will likely push expectations even higher. We are constantly scanning for new technologies—improved continuous flow reactors, next-generation in-process controls, and AI-guided process optimization tools. These not only keep quality high but help us compress lead times and deliver affordably, even as global supply chains grow more complex.
Experience with Rosuvastatin Calcium has taught us the value of robust manufacturing processes, clear communication, and a relentless focus on purity. At every stage, from raw material sourcing to final packaging, we focus on practical outcomes: fewer failed batches, faster blending times, and reliable downstream performance. By investing time and care into each manufacturing decision, we support the growing body of evidence that Rosuvastatin Calcium offers both clinical and operational advantages over many other lipid-lowering agents on the market.
As more nations expand use of statins to prevent heart attack and stroke, we stay committed to raising standards, sharing best practices, and listening to what our partners need. With every new batch, we aim not just for chemical purity but for processes that make a meaningful difference in the hands of our customers and, ultimately, in patient outcomes worldwide.